search
Back to results

Rehabilitation of Airway Protection in Parkinson's Disease

Primary Purpose

Parkinson Disease, Dysphagia

Status
Active
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Expiratory Muscle Strength Training + Cough Skill Training
Sponsored by
Teachers College, Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

50 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Diagnosed with PD (Hoehn and Yahr Stages II-IV)126,127 confirmed by a Movement Disorders fellowship trained neurologist having reviewed the video recorded Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessment for each participant and using strict UK brain bank criteria airway protective deficits as defined as a minimum of penetration of thin liquids (penetration-aspiration score>3) as determined by instrumental swallowing assessment and/or dystussia as determined by voluntary cough assessment (PEFR ≤4.1 L/s) not actively receiving exercise-based swallowing therapy between the ages of 50 and 90. Exclusion criteria: Other neurological disorders (e.g., multiple sclerosis, stroke, brain tumor, etc.) history of head and neck cancer history of breathing disorders or diseases (e.g., COPD) history of smoking in the last five years uncontrolled hypertension difficulty complying due to neuropsychological dysfunction (i.e., severe depression with >28 on the Beck Depression Index (BDI-II), dementia with <19 on the Montreal Cognitive Assessment (MoCA)) allergy to capsaicin or barium further than 1.5 hours (door to door) distance from either Teachers College, Columbia University or Purdue University.

Sites / Locations

  • Purdue University
  • Teachers College, Columbia University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

In-person

Telehealth

Arm Description

Outcomes

Primary Outcome Measures

Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 1
Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 2
Change in Penetration-Aspiration Scale (PAS) - phase 1
PAS, max value: 8 (most impaired), min value 1 (least impaired).
Change in Penetration-Aspiration Scale (PAS) - phase 2
PAS, max value: 8 (most impaired), min value 1 (least impaired).

Secondary Outcome Measures

Change in Maximum Expiratory Pressure - phase 1
Change in Maximum Expiratory Pressure - phase 2
Change in Cough expired volume - phase 1
Change in Cough expired volume - phase 2
Treatment Adherence - phase 1
percent of prescribed training coughs and breaths completed
Change in Treatment Adherence- phase 2
percent of prescribed training coughs and breaths completed
Change in SWAL-QOL- phase 1
self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL
Change in SWAL-QOL - phase 2
self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL

Full Information

First Posted
December 22, 2022
Last Updated
January 17, 2023
Sponsor
Teachers College, Columbia University
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS), Purdue University
search

1. Study Identification

Unique Protocol Identification Number
NCT05700825
Brief Title
Rehabilitation of Airway Protection in Parkinson's Disease
Official Title
Rehabilitation of Airway Protection in Parkinson's Disease: Comparing In-person and Telehealth Service Delivery Models
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 11, 2022 (Actual)
Primary Completion Date
September 1, 2027 (Anticipated)
Study Completion Date
September 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Teachers College, Columbia University
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS), Purdue University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits. The investigators will examine the comparative effectiveness of a novel treatment paradigm delivered in-person versus via telehealth in persons with PD, as well as the role of patient burden and treatment adherence on outcomes; thus, the proposed research is relevant to public health and in line with NIH's mission to identify novel, efficacious, and accessible rehabilitation strategies for short- and long-term improvement of dysfunctional airway protection in PD.
Detailed Description
Progressive disorders of airway protection, such as swallowing disorders (dysphagia) and cough disorders (dystussia), are highly prevalent in PD and have significant negative implications for health and quality of life. In fact, aspiration pneumonia, commonly associated with dysphagia/dystussia, is a leading cause of death in PD. Despite this, there is currently no established standard of care for the treatment of airway protective disorders in this population. Even more critically, approximately 40% of individuals with PD in the United States do not access rehabilitation services or receive specialized care for these potentially life-threatening airway protective deficits. Expiratory Muscle Strength Training (EMST) and Cough Skill Training (CST) have been found to improve airway protective disorders in PD and be feasible via telehealth. However, a significant clinical-research gap remains in that it has not been demonstrated that clinical outcomes are comparable (non-inferior) when these treatments are delivered via telehealth versus in-person. This gap limits access to these important services with detrimental effects to health and quality of life. The long-term goal of this line of research is to improve the health outcomes of individuals with PD, specifically as they relate to airway protective dysfunction. The objective of this application is to pair EMST + CST - and compare clinical and patient-centered outcomes when conducted in-person versus via telehealth in the short- and the long-term. Also, the investigators will assess the role of specific patient burden factors and resultant treatment adherence on clinical outcomes. Therefore, the aims of this study are to: 1) Compare clinical and patient-centered outcomes following four weeks of intensive in-person vs. telehealth EMST+CST treatment in persons with PD, 2) Compare clinical and patient-centered outcomes from a long-term EMST+CST maintenance program offered in-person vs. via telehealth in persons with PD, and 3) Identify the role of specific patient burden factors (i.e., geographic location, cognitive function, disease severity, and caregiver burden) on treatment adherence in the short- and long-term and the influence of treatment adherence on clinical outcomes. The investigators will achieve these aims by conducting a two-arm, two site, randomized clinical trial in 120 people with PD comparing in-person vs. telehealth EMST+CST treatment after a four-week intensive period (aim1) and after a one year maintenance treatment period (with assessments at six and 12 months - aim 2). The investigators anticipate our findings will result in immediately translatable clinical deliverables that will have broad impact for reduced burden and improved accessibility of treatment. Further, these findings will inform our future studies investigating these treatments and service delivery models on long-term outcomes (i.e., aspiration pneumonia, hospitalization, death), accessibility, and healthcare costs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Dysphagia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
In-person
Arm Type
Active Comparator
Arm Title
Telehealth
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Expiratory Muscle Strength Training + Cough Skill Training
Intervention Description
Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles. Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback.
Primary Outcome Measure Information:
Title
Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 1
Time Frame
Pretraining to posttraining (after four weeks of intensive training)
Title
Change in Peak Expiratory Flow Rate (Cough PEFR) - phase 2
Time Frame
post-training to post one-year maintenance
Title
Change in Penetration-Aspiration Scale (PAS) - phase 1
Description
PAS, max value: 8 (most impaired), min value 1 (least impaired).
Time Frame
Pretraining to posttraining (after four weeks of intensive training)
Title
Change in Penetration-Aspiration Scale (PAS) - phase 2
Description
PAS, max value: 8 (most impaired), min value 1 (least impaired).
Time Frame
post-training to post one-year maintenance
Secondary Outcome Measure Information:
Title
Change in Maximum Expiratory Pressure - phase 1
Time Frame
Pretraining to posttraining (after four weeks of intensive training)
Title
Change in Maximum Expiratory Pressure - phase 2
Time Frame
post-training to post one-year maintenance
Title
Change in Cough expired volume - phase 1
Time Frame
Pretraining to posttraining (after four weeks of intensive training)
Title
Change in Cough expired volume - phase 2
Time Frame
post-training to post one-year maintenance
Title
Treatment Adherence - phase 1
Description
percent of prescribed training coughs and breaths completed
Time Frame
posttraining (after four weeks of intensive training)
Title
Change in Treatment Adherence- phase 2
Description
percent of prescribed training coughs and breaths completed
Time Frame
post-training to post one-year maintenance
Title
Change in SWAL-QOL- phase 1
Description
self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL
Time Frame
Pretraining to posttraining (after four weeks of intensive training)
Title
Change in SWAL-QOL - phase 2
Description
self-report questionnaire of swallowing quality of life, 44 min score, 220 max score - higher score is better QOL
Time Frame
post-training to post one-year maintenance

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosed with PD (Hoehn and Yahr Stages II-IV)126,127 confirmed by a Movement Disorders fellowship trained neurologist having reviewed the video recorded Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assessment for each participant and using strict UK brain bank criteria airway protective deficits as defined as a minimum of penetration of thin liquids (penetration-aspiration score>3) as determined by instrumental swallowing assessment and/or dystussia as determined by voluntary cough assessment (PEFR ≤4.1 L/s) not actively receiving exercise-based swallowing therapy between the ages of 50 and 90. Exclusion criteria: Other neurological disorders (e.g., multiple sclerosis, stroke, brain tumor, etc.) history of head and neck cancer history of breathing disorders or diseases (e.g., COPD) history of smoking in the last five years uncontrolled hypertension difficulty complying due to neuropsychological dysfunction (i.e., severe depression with >28 on the Beck Depression Index (BDI-II), dementia with <19 on the Montreal Cognitive Assessment (MoCA)) allergy to capsaicin or barium further than 1.5 hours (door to door) distance from either Teachers College, Columbia University or Purdue University.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Troche, PhD
Organizational Affiliation
Teachers College, Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Purdue University
City
West Lafayette
State/Province
Indiana
ZIP/Postal Code
47907
Country
United States
Facility Name
Teachers College, Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10027
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Rehabilitation of Airway Protection in Parkinson's Disease

We'll reach out to this number within 24 hrs